Bristow Robert G
Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, and Department of Medical Biophysics, University of Toronto, Ont., Canada.
Radiother Oncol. 2004 Feb;70(2):159-64. doi: 10.1016/j.radonc.2004.02.002.
The use of molecular medicine is now merging into clinical practice with the advent of molecular targeting agents, molecular pathology and molecular imaging for both diagnosis and treatment response. Radiation oncologists must therefore gain expertise in utilizing this information to drive new treatment protocols. Recognizing the importance of this issue, the Canadian Association of Radiation Oncologists (CARO) charged a Task Force in Translational Radiobiology to: (1) critically assess training programs and research infrastructure in relation to current and future translational radiobiology requirements; and (2) make specific recommendations to accelerate the implementation of translational science into day-to-day practice. Selected Task Force recommendations included the principle that universities and departmental Chairs increase the opportunities for academic promotion, funding, and tenure track positions of radiobiologists and translational radiation oncologists. The dedication of 4 to 5 national centers as translational 'hubs', can serve as an interface between clinicians, clinical specimens and radiobiological sciences within the context of correlative clinical trials. The model of the clinician-scientist was encouraged as an important adjunct to good clinical care to be associated with strong enticement, training and mentoring programs and 75%-protected research time. Finally, an integrated model of radiobiological training programs and mutual continuing education between clinicians and basic scientists can be facilitated through a new national radiobiology meeting sponsored by CARO. These recommendations have been accepted by the national radiation oncology membership. Such a framework may serve useful for national programs wishing to develop rapid conduits from the lab to the clinic as a means of integrating molecular biology and the day-to-day practice of radiation oncology.
随着分子靶向药物、分子病理学以及用于诊断和治疗反应评估的分子成像技术的出现,分子医学正在融入临床实践。因此,放射肿瘤学家必须掌握利用这些信息来推动新治疗方案的专业知识。认识到这一问题的重要性,加拿大放射肿瘤学家协会(CARO)责成一个转化放射生物学特别工作组:(1)严格评估与当前及未来转化放射生物学需求相关的培训项目和研究基础设施;(2)提出具体建议,以加速将转化科学应用于日常实践。特别工作组的部分建议包括:大学和系主任应增加放射生物学家和转化放射肿瘤学家在学术晋升、资金获取和终身教职岗位方面的机会。设立4至5个全国性的转化“中心”,可在相关临床试验的背景下,作为临床医生、临床标本与放射生物学之间的接口。鼓励采用临床科学家模式,作为优质临床护理的重要补充,并配以强大的激励、培训和指导计划以及75%的科研时间保障。最后,通过CARO主办的新的全国放射生物学会议,可推动放射生物学培训项目以及临床医生和基础科学家之间相互继续教育的综合模式。这些建议已被全国放射肿瘤学界成员接受。这样一个框架可能对那些希望建立从实验室到临床的快速通道,以整合分子生物学与放射肿瘤学日常实践的国家项目有用。